期刊
EXPERIMENTAL CELL RESEARCH
卷 369, 期 1, 页码 1-10出版社
ELSEVIER INC
DOI: 10.1016/j.yexcr.2018.05.009
关键词
CARs; Chimeric antigen receptors; Tumor antigens; Immunotherapy; Adoptive T cell transfer
资金
- Iranian National Institute for Medical Research Development, NIMAD [940999]
- Digestive Disease Research Institute [301/579]
- Tehran University of Medical Sciences [301/579]
Chimeric antigen receptor (CAR) T cell therapy is anticipated to be increasingly implemented in the context of cancer treatment after two current FDA approval of anti-CD19 CAR-T cells (Kymriah (TM)& Yescarta (TM)). The success of CD19 is mainly attributable to the proper selection of the antigen, CD19, as the target of the disease, highlighting the importance of target selection for other CAR therapies. Therefore, here we performed a global analysis of targets that are the prime focus for various CAR T cell therapies in human clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据